EUVIMEDEUVIMED entdecken
Crossref

Do Comparative Efficacy Trials Still Resolve Meaningful Uncertainty in Biosimilar Development and Regulatory Decision-Making? A Critical Evidence Review

Aisha Bello, Zainab Sule, Ibrahim Musa, Grace Adeyemi, Ahmed Youssef

International Journal of Pharmaceutical Research and Allied Sciences · 2026 · 15 (1) · 33-43

DOI: 10.51847/4fl1lem9bq ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Research and Allied Sciences, 2026. Verfasst von Aisha Bello und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comparative efficacy trials have historically served as visible clinical confirmation within biosimilar development, but their incremental scientific value has become increasingly contested as analytical characterization, functional testing, pharmacokinetic comparison, pharmacodynamic biomarkers, and immunogenicity assessment have become more sensitive. This critical evidence review evaluates whether comparative efficacy trials still resolve uncertainties that materially affect biosimilar develo

Zitieren

APA

Bello, A., Sule, Z., Musa, I., Adeyemi, G., & Youssef, A. (2026). Do Comparative Efficacy Trials Still Resolve Meaningful Uncertainty in Biosimilar Development and Regulatory Decision-Making? A Critical Evidence Review. International Journal of Pharmaceutical Research and Allied Sciences, 15(1), 33-43. https://doi.org/10.51847/4fl1lem9bq

Vancouver

Bello A, Sule Z, Musa I, Adeyemi G, Youssef A. Do Comparative Efficacy Trials Still Resolve Meaningful Uncertainty in Biosimilar Development and Regulatory Decision-Making? A Critical Evidence Review. International Journal of Pharmaceutical Research and Allied Sciences. 2026;15(1):33-43. doi:10.51847/4fl1lem9bq

BibTeX
@article{Bello2026,
  author = {Bello, Aisha and Sule, Zainab and Musa, Ibrahim and Adeyemi, Grace and Youssef, Ahmed},
  title = {Do Comparative Efficacy Trials Still Resolve Meaningful Uncertainty in Biosimilar Development and Regulatory Decision-Making? A Critical Evidence Review},
  journal = {International Journal of Pharmaceutical Research and Allied Sciences},
  year = {2026},
  volume = {15},
  number = {1},
  pages = {33--43},
  doi = {10.51847/4fl1lem9bq}
}
Kostenlos starten →